Abstract
A proteome profiling of the epithelial ovarian cancer cell line TOV-112D was initiated as a protein expression reference in the study of ovarian cancer. Two complementary proteomic approaches were used in order to maximise protein identification: two-dimensional gel electrophoresis (2DE) protein separation coupled to matrix assisted laser desorption/ionisation time-of-flight mass spectrometry (MALDI-TOF MS) and one-dimensional gel electrophoresis (1DE) coupled to liquid-chromatography tandem mass spectrometry (LC MS/MS). One hundred and seventy-two proteins have been identified among 288 spots selected on two-dimensional gels and a total of 579 proteins were identified with the 1DE LC MS/MS approach. This proteome profiling covers a wide range of protein expression and identifies several proteins known for their oncogenic properties. Bioinformatics tools were used to mine databases in order to determine whether the identified proteins have previously been implicated in pathways associated with carcinogenesis or cell proliferation. Indeed, several of the proteins have been reported to be specific ovarian cancer markers while others are common to many tumorigenic tissues or proliferating cells. The diversity of proteins found and their association with known oncogenic pathways validate this proteomic approach. The proteome 2D map of the TOV-112D cell line will provide a valuable resource in studies on differential protein expression of human ovarian carcinomas while the 1DE LC MS/MS approach gives a picture of the actual protein profile of the TOV-112D cell line. This work represents one of the most complete ovarian protein expression analysis reports to date and the first comparative study of gene expression profiling and proteomic patterns in ovarian cancer.
Similar content being viewed by others
References
Whitman G, Nolan T, Gallup D: Normal ovarian development and function. In: M. Markman, W.J. Hoskins (eds). Cancer of the Ovary. Raven Press, New York, 1993
Chang J, Fryatt I, Ponder B, Fisher C, Gore ME: A matched control study of familial epithelial ovarian cancer: Patient characteristics, response to chemotherapy and outcome. Ann Oncol 6: 80–82, 1995
Kaku T, Ogawa S, Kawano Y, Ohishi Y, Kobayashi H, Hirakawa T, Nakano H: Histological classification of ovarian cancer. Med Electron Microsc 36: 9–17, 2003
Provencher DM, Lounis H, Champoux L, Tetrault M, Manderson EN, Wang JC, Eydoux P, Savoie R, Tonin PN, Mes-Masson AM: Characterization of four novel epithelial ovarian cancer cell lines. In Vitro Cell Dev Biol Anim 36: 357–361, 2000
Keller A, Nesvizhskii AI, Kolker E, Aebersold R: Empirical statistical model to estimate the accuracy of peptide identifications made by MS/MS and database search. Anal Chem 74: 5383–5392, 2002
Von Haller PD, Yi E, Donohoe S, Vaughn K, Keller A, Nesvizhskii AI, Eng J, Li XJ, Goodlett DR, Aebersold R, Watts JD: The application of new software tools to quantitative protein profiling via Isotope-coded Affinity Tag (ICAT) and Tandem Mass Spectrometry: II. Evaluation of Tandem Mass Spectrometry Methodologies for Large-Scale Protein Analysis, and the Application of Statistical Tools for Data Analysis and Interpretation. Mol Cell Proteomics 2: 428–442, 2003
Nesvizhskii AI, Keller A, Kolker E, Aebersold R: A statistical model for identifying proteins by tandem mass spectrometry. Anal Chem 75: 4646–4658, 2003
Conroy SE, Latchman DS: Do heat shock proteins have a role in breast cancer? Br J Cancer 74: 717–721, 1996
Le Page C, Provencher D, Maugard CM, Ouellet V, Mes-Masson AM: Signature of a silent killer: Expression profiling in epithelial ovarian cancer. Expert Rev Mol Diagn 4: 157–167, 2004
Tonin PN, Hudson TJ, Rodier F, Bossolasco M, Lee PD, Novak J, Manderson EN, Provencher D, Mes-Masson AM: Microarray analysis of gene expression mirrors the biology of an ovarian cancer model. Oncogene 20: 6617–6626, 2001
Sladek NE, Kollander R, Sreerama L, Kiang DT: Cellular levels of aldehyde dehydrogenases (ALDH1A1 and ALDH3A1) as predictors of therapeutic responses to cyclophosphamide-based chemotherapy of breast cancer: A retrospective study. Rational individualization of oxazaphosphorine-based cancer chemotherapeutic regimens. Cancer Chemother Pharmacol 49: 309–321, 2002
Bergman AC, Benjamin T, Alaiya A, Waltham M, Sakaguchi K, Franzen B, Linder S, Bergman T, Auer G, Appella E, Wirth PJ, Jornvall H: Identification of gel-separated tumor marker proteins by mass spectrometry. Electrophoresis 21: 679–686, 2000
Altenberg B, Greulich KO: Genes of glycolysis are ubiquitously overexpressed in 24 cancer classes. Genomics 84: 1014–1020, 2004
Jones MB, Krutzsch H, Shu H, Zhao Y, Liotta LA, Kohn EC, Petricoin EF, 3rd: Proteomic analysis and identification of new biomarkers and therapeutic targets for invasive ovarian cancer. Proteomics 2: 76–84, 2002
Alaiya AA, Franzen B, Fujioka K, Moberger B, Schedvins K, Silfversvard C, Linder S, Auer G: Phenotypic analysis of ovarian carcinoma: Polypeptide expression in benign, borderline and malignant tumors. Int J Cancer 73: 678–683, 1997
Tomic S, Ilic Forko J, Babic D, Sundov D, Kuret S, Andelinovic S: c-erbB-2, p53, and nm23 proteins as prognostic factors in patients with epithelial ovarian carcinoma. Croat Med J 44: 429–434, 2003
Simone G, Falco G, Caponio MA, Campobasso C, De Frenza M, Petroni S, Wiesel S, Leone A: nm23 expression in malignant ascitic effusions of serous ovarian adenocarcinoma. Int J Oncol 19: 885–890, 2001
Schneider J, Pollan M, Jimenez E, Marenbach K, Martinez N, Volm M, Marx D, Meden H: nm23-H1 expression defines a high-risk subpopulation of patients with early-stage epithelial ovarian carcinoma. Br J Cancer 82: 1662–1670, 2000
Qian M, Feng Y, Xu L, Zheng S, Zhou X: Expression of antimetastatic gene nm23-H1 in epithelial ovarian cancer. Chin Med J (Engl) 110: 142–144, 1997
Stierum R, Gaspari M, Dommels Y, Ouatas T, Pluk H, Jespersen S, Vogels J, Verhoeckx K, Groten J, van Ommen B: Proteome analysis reveals novel proteins associated with proliferation and differentiation of the colorectal cancer cell line Caco-2. Biochim Biophys Acta 1650: 73–91, 2003
Yow HK, Wong JM, Chen HS, Lee CG, Davis S, Steele GD, Jr., Chen LB: Increased mRNA expression of a laminin-binding protein in human colon carcinoma: Complete sequence of a full-length cDNA encoding the protein. Proc Natl Acad Sci USA 85: 6394–6398, 1988
Mathur S, Cleary KR, Inamdar N, Kim YH, Steck P, Frazier ML: Overexpression of elongation factor-1gamma protein in colorectal carcinoma. Cancer 82: 816–821, 1998
Zhang Y, Woodford N, Xia X, Hamburger AW: Repression of E2F1-mediated transcription by the ErbB3 binding protein Ebp1 involves histone deacetylases. Nucleic Acids Res 31: 2168–2177, 2003
Hirst M, Haliday E, Nakamura J, Lou L: Human GMP synthetase. Protein purification, cloning, and functional expression of cDNA. J Biol Chem 269: 23830–23837, 1994
Wells J, Henkler F, Leversha M, Koshy R: A mitochondrial elongation factor-like protein is over-expressed in tumours and differentially expressed in normal tissues. FEBS Lett 358: 119–125, 1995
Fukuda S, Wu DW, Stark K, Pelus LM: Cloning and characterization of a proliferation-associated cytokine-inducible protein, CIP29. Biochem Biophys Res Commun 292: 593–600, 2002
Fujii J, Ikeda Y: Advances in our understanding of peroxiredoxin, a multifunctional, mammalian redox protein. Redox Rep 7: 123–130, 2002
Yanai Y, Micallef MJ, Yamamoto S, Yamamoto K, Yamauchi H, Ikegami H, Kurimoto M: Expression profiling of tumor necrosis factor alpha-induced apoptosis-associated genes in human solid tumor cell lines. Anticancer Res 23: 2339–2348, 2003
Rosenquist M: 14-3-3 proteins in apoptosis. Braz J Med Biol Res 36: 403–408, 2003
Weis K: Regulating access to the genome: Nucleocytoplasmic transport throughout the cell cycle. Cell 112: 441–451, 2003
Rosenfeld JL, Knoll BJ, Moore RH: Regulation of G-protein-coupled receptor activity by rab GTPases. Receptors Channels 8: 87–97, 2002
McClung JK, King RL, Walker LS, Danner DB, Nuell MJ, Stewart CA, Dell’Orco RT: Expression of prohibitin, an antiproliferative protein. Exp Gerontol 27: 413–417, 1992
Wang S, Nath N, Adlam M, Chellappan S: Prohibitin, a potential tumor suppressor, interacts with RB and regulates E2F function. Oncogene 18: 3501–3510, 1999
Jupe ER, Liu XT, Kiehlbauch JL, McClung JK, Dell’Orco RT: Prohibitin in breast cancer cell lines: Loss of antiproliferative activity is linked to 3′ untranslated region mutations. Cell Growth Differ 7: 871–878, 1996
Wu Y, Pan S, Che S, He G, Nelman-Gonzalez M, Weil MM, Kuang J: Overexpression of Hp95 induces G1 phase arrest in confluent HeLa cells. Differentiation 67: 139–153, 2001
Leonard GD, Low JA, Berman AW, Swain SM: CA 125 elevation in breast cancer: A case report and review of the literature. Breast J 10: 146–149, 2004
Sun HT, Cohen S, Kaufmann WE: Annexin-1 is abnormally expressed in fragile X syndrome: Two-dimensional electrophoresis study in lymphocytes. Am J Med Genet 103: 81–90, 2001
Oh P, Li Y, Yu J, Durr E, Krasinska KM, Carver LA, Testa JE, Schnitzer JE: Subtractive proteomic mapping of the endothelial surface in lung and solid tumours for tissue-specific therapy. Nature 429: 629–635, 2004
Eng J, McCormack A, Yates JR, III: An approach to correlate tandem mass spectral data of peptides with amino acid sequences in a protein database. J Am Soc Mass Spectrom 5: 976–989, 1994
Tamayo P, Slonim D, Mesirov J, Zhu Q, Kitareewan S, Dmitrovsky E, Lander ES, Golub TR: Interpreting patterns of gene expression with self-organizing maps: Methods and application to hematopoietic differentiation. Proc Natl Acad Sci USA 96: 2907–2912, 1999
Novak P, Sladek R, Hudson TJ: Characterization of variability in large-scale gene expression data: Implications for study design. Genomics 79: 104–113, 2002
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Gagné, JP., Gagné, P., Hunter, J.M. et al. Proteome profiling of human epithelial ovarian cancer cell line TOV-112D. Mol Cell Biochem 275, 25–55 (2005). https://doi.org/10.1007/s11010-005-7556-1
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/s11010-005-7556-1